Lupus Clinical Trials

Showing 2501-2520 of 3,134 trials

Home Nasal Pressure for Sleep Apnea Management in Primary Case

NCT02141165

Primary objectives: To determine the efficacy and cost-effectiveness of a management program for patients with obstructive sleep apnea syndrome (OSAS) carried out in primary or specialist healthcare. In the primary arm, the diagnosis and therapeutic decision will be made by means of a domiciliary nasal pressure (DNP) channel and oximetry while the specialist healthcare arm will use polysomnography (PSG) in a hospital. Patients with an intermediate-high suspicion of OSAS will be included, taking as primary variables the Epworth scale, for efficacy, and the Epworth scale and EuroQol 5D, for cost-effectiveness. Secondary objectives: efficacy of the two SAHS management programs according to the following secondary variables: a) quality-of-life tests: FOSQ questionnaire, SF36 and analogical wellbeing scale, b) adherence to and compliance with the treatment.

Obstructive Sleep Apnea Syndrome

Sociedad Española de Neumología y Cirugía Torácica280 participantsStarted Mar 2014

Cáceres, Cáceres, Spain

COMPLETEDPhase 4

Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness

NCT02578186

The present study was conducted to investigate the impact of diphenhydramine hydrochloride on the ability to initiate sleep.

Occasional Sleeplessness

Procter and Gamble33 participantsStarted Nov 2013

COMPLETEDPhase 2

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

NCT00092404

The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.

MeaslesMumpsRubella+1 more

Merck Sharp & Dohme LLC1,210 participantsStarted Dec 2001

COMPLETEDPhase 4

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

NCT00432731

Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination. Secondary objectives: NA

VaricellaMeaslesMumps+1 more

Merck Sharp & Dohme LLC500 participantsStarted Dec 2004

Amboise, France • Ancenis, France • Betton, France +22 more locations

Home Nasal Pressure for Sleep Apnea Management in Primary Case

Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Related Searches

Nasal Obstruction in Sleep Apnea Patients Compared to the General Population

Melatonin Treatment for Induced Transient Insomnia

Effects of Melatonin on Insomnia Symptoms in Older Adults

Assessment of Sleep Apnea and Its Causes Before and After Weight Loss Surgery

Safety of an Early Discharge Protocol After Sleeve Gastrectomy

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Combination Therapy to Treat Sleep Apnea

Anti-ficolin-2 Autoantibodies in Lupus Nephritis

The Effects of Trazodone on Sleep Apnea Severity

Sleep Wake and Melatonin Pattern in Craniopharyngioma

Sleep and Stent Study: a Multicentre, Prospective Study

Yoga in Treating Sleep Disturbance in Cancer Survivors

Sleep Disordered Breathing

Glutathione and Health With Post-Polio Syndrome

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects